Strong Revenue and Volume Growth
Revenue increased by 9% in Q4 2024, driven by a 13% volume growth. Overall, 2024 saw a 21% increase in volume, indicating significant growth across segments and customers.
Adjusted EBITDA Improvement
Adjusted EBITDA increased by 20% in Q4 2024. The EBITDA margin improved by 130 basis points to 13.4%, supported by strong revenue growth and operational efficiencies.
Successful Midlothian Startup Completion
The startup phase at Midlothian was completed, with electrical distribution equipment upgrades finalized, enhancing operational capacity.
Debt Reduction and Cash Flow Generation
Debt was reduced by $25 million, achieving a net leverage target of 3 times. Cash provided by operating activities increased significantly to $52 million from $4 million in 2023.
Future Growth and Efficiency Plans
Plans to increase aseptic processing capacity by 20% by the end of 2026 and achieve a $125 million adjusted EBITDA annual run rate by the end of 2025.